This innovative Exo‐based delivery platform offers a promising strategy for achieving stable STING pathway activation and precise immune modulation within the TME using a single integrated system, ultimately improving the efficacy and safety of pancreatic cancer immunotherapy. This evidence concerns the gene STING1 and pancreatic neoplasm.